| Year |
Citation |
Score |
| 2024 |
Galldiks N, Kaufmann TJ, Vollmuth P, Lohmann P, Smits M, Veronesi MC, Langen KJ, Rudá R, Albert NL, Hattingen E, Law I, Hutterer M, Soffietti R, Vogelbaum MA, Wen PY, ... ... Tonn JC, et al. Challenges, Limitations and Pitfalls of PET and Advanced MRI in Patients with Brain Tumors - A Report of the PET/RANO Group. Neuro-Oncology. PMID 38466087 DOI: 10.1093/neuonc/noae049 |
0.384 |
|
| 2024 |
Gold L, Barci E, Brendel M, Orth M, Cheng J, Kirchleitner SV, Bartos LM, Pötter D, Kirchner MA, Unterrainer LM, Kaiser L, Ziegler S, Weidner L, Riemenschneider MJ, Unterrainer M, ... ... Tonn JC, et al. The Traumatic Inoculation Process Affects TSPO Radioligand Uptake in Experimental Orthotopic Glioblastoma. Biomedicines. 12. PMID 38255293 DOI: 10.3390/biomedicines12010188 |
0.668 |
|
| 2024 |
Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short SC, ... ... Tonn JC, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. The Lancet. Oncology. 25: e29-e41. PMID 38181810 DOI: 10.1016/S1470-2045(23)00525-9 |
0.618 |
|
| 2023 |
Karschnia P, Smits M, Reifenberger G, Le Rhun E, Ellingson BM, Galldiks N, Kim MM, Huse JT, Schnell O, Harter PN, Mohme M, von Baumgarten L, Albert NL, Huang RY, Mehta MP, ... ... Tonn JC, et al. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups. The Lancet. Oncology. 24: e438-e450. PMID 37922934 DOI: 10.1016/S1470-2045(23)00453-9 |
0.528 |
|
| 2023 |
Weidner L, Lorenz J, Quach S, Braun FK, Rothhammer-Hampl T, Ammer LM, Vollmann-Zwerenz A, Bartos LM, Dekorsy FJ, Holzgreve A, Kirchleitner SV, Thon N, Greve T, Ruf V, Herms J, ... ... Tonn JC, et al. Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages. Acta Neuropathologica Communications. 11: 147. PMID 37697350 DOI: 10.1186/s40478-023-01651-5 |
0.664 |
|
| 2023 |
Unterrainer M, Kunte SC, Unterrainer LM, Holzgreve A, Delker A, Lindner S, Beyer L, Brendel M, Kunz WG, Winkelmann M, Cyran CC, Ricke J, Jurkschat K, Wängler C, Wängler B, ... ... Tonn JC, et al. Correction to: Next‑generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR‑targeting peptide [F]SiTATE. European Journal of Nuclear Medicine and Molecular Imaging. PMID 37642707 DOI: 10.1007/s00259-023-06409-8 |
0.675 |
|
| 2023 |
Teske N, Biczok A, Quach S, Dekorsy FJ, Forbrig R, Bodensohn R, Niyazi M, Tonn JC, Albert NL, Schichor C, Ueberschaer M. Postoperative [Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1. European Journal of Nuclear Medicine and Molecular Imaging. PMID 37642702 DOI: 10.1007/s00259-023-06400-3 |
0.635 |
|
| 2023 |
Albert NL, Nelwan DV, Fleischmann DF, Quach S, von Rohr K, Kaiser L, Teske N, Unterrainer LM, Bartos LM, Ruf VC, Brendel M, Riemenschneider MJ, Wetzel C, Herms J, Rupprecht R, ... ... Tonn JC, et al. Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type Glioblastoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 37536737 DOI: 10.2967/jnumed.122.265247 |
0.7 |
|
| 2023 |
Unterrainer M, Kunte SC, Unterrainer LM, Holzgreve A, Delker A, Lindner S, Beyer L, Brendel M, Kunz WG, Winkelmann M, Cyran CC, Ricke J, Jurkschat K, Wängler C, Wängler B, ... ... Tonn JC, et al. Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [F]SiTATE. European Journal of Nuclear Medicine and Molecular Imaging. PMID 37358620 DOI: 10.1007/s00259-023-06315-z |
0.691 |
|
| 2023 |
Blobner J, Dengler L, Blobner S, Eberle C, Weller J, Teske N, Karschnia P, Rühlmann K, Heinrich K, Ziemann F, Greif PA, Jeremias I, Wuerstlein R, Hasselmann K, Dorostkar M, ... ... Tonn JC, et al. Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma. Neuro-Oncology Advances. 5: vdad060. PMID 37287694 DOI: 10.1093/noajnl/vdad060 |
0.523 |
|
| 2023 |
Galldiks N, Albert NL, Wollring M, Werner JM, Lohmann P, Villanueva-Meyer JE, Fink GR, Langen KJ, Tonn JC. Advances in PET imaging for meningioma patients. Neuro-Oncology Advances. 5: i84-i93. PMID 37287577 DOI: 10.1093/noajnl/vdac113 |
0.625 |
|
| 2023 |
Menevse AN, Ammer LM, Vollmann-Zwerenz A, Kupczyk M, Lorenz J, Weidner L, Hussein A, Sax J, Mühlbauer J, Heuschneider N, Rohrmus C, Mai LS, Jachnik B, Stamova S, Volpin V, ... ... Tonn JC, et al. TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastoma. Acta Neuropathologica Communications. 11: 75. PMID 37158962 DOI: 10.1186/s40478-023-01550-9 |
0.552 |
|
| 2023 |
Zounek AJ, Albert NL, Holzgreve A, Unterrainer M, Brosch-Lenz J, Lindner S, Bollenbacher A, Boening G, Rupprecht R, Brendel M, von Baumgarten L, Tonn JC, Bartenstein P, Ziegler S, Kaiser L. Feasibility of radiomic feature harmonization for pooling of [F]FET or [F]GE-180 PET images of gliomas. Zeitschrift Fur Medizinische Physik. PMID 36710156 DOI: 10.1016/j.zemedi.2022.12.005 |
0.656 |
|
| 2022 |
Katzendobler S, Do A, Weller J, Rejeski K, Dorostkar MM, Albert NL, Forbrig R, Niyazi M, Egensperger R, Tonn JC, von Baumgarten L, Quach S, Thon N. The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine. Frontiers in Oncology. 12: 1014711. PMID 36605448 DOI: 10.3389/fonc.2022.1014711 |
0.554 |
|
| 2022 |
Teske N, Albert NL, Forbrig R, Teske NC, von Baumgarten L, Kunz WG, Tonn JC, Thon N, Karschnia P. Advanced imaging findings in stroke-like migraine attacks after radiation therapy (SMART) syndrome. European Journal of Nuclear Medicine and Molecular Imaging. PMID 36418589 DOI: 10.1007/s00259-022-06042-x |
0.462 |
|
| 2022 |
Quach S, Holzgreve A, Kaiser L, Unterrainer M, Dekorsy FJ, Nelwan DV, Bartos LM, Kirchleitner SV, Weller J, Weidner L, Niyazi M, Ruf VC, Herms J, Stöcklein S, Wetzel C, ... ... Tonn JC, et al. TSPO PET signal using [F]GE180 is associated with survival in recurrent gliomas. European Journal of Nuclear Medicine and Molecular Imaging. PMID 36329288 DOI: 10.1007/s00259-022-06006-1 |
0.695 |
|
| 2022 |
von Rohr K, Unterrainer M, Holzgreve A, Kirchner MA, Li Z, Unterrainer LM, Suchorska B, Brendel M, Tonn JC, Bartenstein P, Ziegler S, Albert NL, Kaiser L. Can Radiomics Provide Additional Information in [F]FET-Negative Gliomas? Cancers. 14. PMID 36230783 DOI: 10.3390/cancers14194860 |
0.675 |
|
| 2022 |
Li Z, Holzgreve A, Unterrainer LM, Ruf VC, Quach S, Bartos LM, Suchorska B, Niyazi M, Wenter V, Herms J, Bartenstein P, Tonn JC, Unterrainer M, Albert NL, Kaiser L. Combination of pre-treatment dynamic [F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging. PMID 36227357 DOI: 10.1007/s00259-022-05988-2 |
0.67 |
|
| 2022 |
Katzendobler S, Do A, Weller J, Dorostkar MM, Albert NL, Forbrig R, Niyazi M, Egensperger R, Thon N, Tonn JC, Quach S. Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas. Frontiers in Neurology. 13: 822362. PMID 35432168 DOI: 10.3389/fneur.2022.822362 |
0.514 |
|
| 2021 |
Mittlmeier LM, Suchorska B, Ruf V, Holzgreve A, Brendel M, Herms J, Bartenstein P, Tonn JC, Unterrainer M, Albert NL. F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors. Cancers. 13. PMID 34202726 DOI: 10.3390/cancers13133163 |
0.688 |
|
| 2021 |
Vettermann FJ, Harris S, Schmitt J, Unterrainer M, Lindner S, Rauchmann BS, Palleis C, Weidinger E, Beyer L, Eckenweber F, Schuster S, Biechele G, Ferschmann C, Milenkovic VM, Wetzel CH, ... ... Tonn JC, et al. Impact of TSPO Receptor Polymorphism on [F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. Life (Basel, Switzerland). 11. PMID 34073557 DOI: 10.3390/life11060484 |
0.615 |
|
| 2020 |
Vettermann FJ, Unterrainer M, Ruf V, Fleischmann DF, Rupprecht R, Forbrig R, Herms J, Tonn JC, Belka C, Bartenstein P, Niyazi M, Albert NL. Dual PET Imaging of an H3K27M-Mutant Glioma With 18F-GE-180 and 18F-FET PET. Clinical Nuclear Medicine. PMID 33065624 DOI: 10.1097/RLU.0000000000003331 |
0.711 |
|
| 2020 |
Stoecklein VM, Stoecklein S, Galiè F, Ren J, Schmutzer M, Unterrainer M, Albert NL, Kreth FW, Thon N, Liebig T, Ertl-Wagner B, Tonn JC, Liu H. Resting-state fMRI Detects Alterations in Whole Brain Connectivity Related to Tumor Biology in Glioma Patients. Neuro-Oncology. PMID 32107555 DOI: 10.1093/neuonc/noaa044 |
0.509 |
|
| 2019 |
Unterrainer M, Ruf V, Cyran CC, Brendel M, Thon N, Herms J, Schüller U, Tonn JC, Bartenstein P, Albert NL. Identification of Distant Metastases From Recurrent Gliosarcoma Using Whole-Body 18F-FDG PET/CT. Clinical Nuclear Medicine. 44: 923-924. PMID 31584491 DOI: 10.1097/Rlu.0000000000002790 |
0.701 |
|
| 2019 |
Unterrainer M, Ruf V, Ilhan H, Vettermann F, Holzgreve A, Cyran CC, Tonn JC, Bartenstein P, Albert NL. Teaching NeuroImages: Advanced imaging of neurosarcoidosis with Ga-DOTATATE PET/CT. Neurology. 92: e2512-e2513. PMID 31110154 DOI: 10.1212/WNL.0000000000007544 |
0.652 |
|
| 2019 |
Unterrainer M, Ruf V, Ilhan H, Vettermann FJ, Cyran CC, Niyazi M, Bartenstein P, Tonn JC, Albert NL. 68Ga-DOTATOC PET/CT Differentiates Meningioma From Dural Metastases. Clinical Nuclear Medicine. 44: 412-413. PMID 30829858 DOI: 10.1097/RLU.0000000000002513 |
0.621 |
|
| 2019 |
Unterrainer M, Ilhan H, Vettermann F, Cyran CC, Tonn JC, Niyazi M, Bartenstein P, Albert NL. Whole-Body Staging of Metastatic Atypical Meningioma Using 68Ga-DOTATATE PET/CT. Clinical Nuclear Medicine. 44: 227-228. PMID 30589668 DOI: 10.1097/RLU.0000000000002422 |
0.609 |
|
| 2018 |
Unterrainer M, Fleischmann DF, Lindner S, Brendel M, Rupprecht R, Tonn JC, Belka C, Bartenstein P, Niyazi M, Albert NL. Detection of Cerebrospinal Fluid Dissemination of Recurrent Glioblastoma Using TSPO-PET With 18F-GE-180. Clinical Nuclear Medicine. 43: 518-519. PMID 29742608 DOI: 10.1097/RLU.0000000000002113 |
0.703 |
|
| 2018 |
Suchorska B, Schüller U, Biczok A, Kreth FW, Lenski M, Albert NL, Giese A, Ertl-Wagner B, Ingrisch M, Tonn J. Contrast enhancement as a prognostic factor in IDH1/2 mutant glioma. Journal of Clinical Oncology. 36: 2029-2029. DOI: 10.1200/JCO.2018.36.15_SUPPL.2029 |
0.484 |
|
| 2017 |
Suchorska B, Unterrainer M, Biczok A, Albert N, Tonn J, Kreth F. NIMG-100. USEFULNESS OF 18FET-PET FOR CHEMOTHERAPY MONITORING IN NON-CONTRAST ENHANCING GLIOMA Neuro-Oncology. 19: vi165-vi165. DOI: 10.1093/NEUONC/NOX168.669 |
0.615 |
|
| 2017 |
Suchorska B, Sosnova M, Unterrainer M, Biczok A, Bartenstein P, Albert N, Tonn J. NIMG-39. PATTERNS OF INTERSECTIONAL TUMOUR VOLUME IN T2-WEIGHTED MRI AND 18F-FET PET CORRELATE WITH OUTCOME IN GLIOBLASTOMA Neuro-Oncology. 19: vi150-vi150. DOI: 10.1093/NEUONC/NOX168.614 |
0.65 |
|
| 2016 |
Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology. PMID 27106405 DOI: 10.1093/Neuonc/Now058 |
0.663 |
|
| 2016 |
Suchorska B, Kraus T, Biczok A, Weller M, Unterrainer M, Schueller U, Schmid-Tannwald C, Bartenstein P, Giese A, Tonn J, Albert NL. Correlation of IDH mutation, 1p/19q co-deletion and 18FET-PET derived time-to-peak analysis as prognostic markers in glioma Journal of Clinical Oncology. 34: 2058-2058. DOI: 10.1200/JCO.2016.34.15_SUPPL.2058 |
0.614 |
|
| 2016 |
Suchorska B, Kraus T, Biczok A, Weller M, Unterrainer M, Schüller U, Schmid-Tannwald C, Bartenstein P, Giese A, Albert N, Tonn J. NIMG-34. 18FET-PET UPTAKE DYNAMICS SERVES AS AN ADDITIONAL IMAGING BIOMARKER IN ASTROCYTOMAS WITH IDH1/2 MUTATION AND NO LOH1p/19q Neuro-Oncology. 18: vi131-vi132. DOI: 10.1093/neuonc/now212.546 |
0.649 |
|
| 2016 |
Suchorska B, Biczok A, Lenski M, Albert NL, Schüller U, Tonn J. P07.16 Prognostic value of contrast enhancement and histopathological grading in diffuse gliomas depends on IDH1/2 mutation Neuro-Oncology. 18: iv37-iv37. DOI: 10.1093/NEUONC/NOW188.127 |
0.495 |
|
| 2015 |
Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, Simon M, Pöpperl G, Kreth FW, la Fougere C, Weller M, Tonn JC. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 84: 710-9. PMID 25609769 DOI: 10.1212/WNL.0000000000001262 |
0.455 |
|
| 2015 |
Suchorska B, Jansen NL, Kraus T, Giese A, Bartenstein P, Tonn J. Correlation of dynamic 18FET-PET with IDH 1 mutation for prediction of outcome in anaplastic astrocytoma WHO° III independently from tumor vascularisation. Journal of Clinical Oncology. 33: 2037-2037. DOI: 10.1200/JCO.2015.33.15_SUPPL.2037 |
0.474 |
|
| 2014 |
Tonn J, Rachinger W, Thon N, Terpolilli N, Haug A, Ertl L, Poeschl J, Schueller U, Schichor C. Increased 68Ga-DOTATATE uptake in PET imaging to discriminate meningioma and tumor-free tissue. Journal of Clinical Oncology. 32: e13020-e13020. DOI: 10.1200/JCO.2014.32.15_SUPPL.E13020 |
0.355 |
|
| 2014 |
Suchorska B, Jansen NL, Sosnova M, Janssen H, Grabowski M, Kreth F, Vogelbaum MA, Tonn J. NI-72 * CORRELATION OF VOLUMETRICAL ANALYSES DERIVED FROM 18FET-PET AND MRI WITH OUTCOME IN GLIOBLASTOMA PATIENTS Neuro-Oncology. 16: v154-v154. DOI: 10.1093/NEUONC/NOU264.70 |
0.31 |
|
| 2014 |
Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Niyazi M, Bartenstein P, Kreth F, Fougere CL, Tonn J. NI-41 * PROGNOSTIC SIGNIFICANCE OF DYNAMIC ANALYSIS OF 18FET-PET IN NEWLY DIAGNOSED HIGH GRADE GLIOMA Neuro-Oncology. 16: v147-v147. DOI: 10.1093/neuonc/nou264.39 |
0.517 |
|
| 2008 |
Mehrkens JH, Pp̈pperl G, Rachinger W, Herms J, Seelos K, Tatsch K, Tonn JC, Kreth FW. The positive predictive value of O-(2-[18F]fluoroethyl)-l- tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment Journal of Neuro-Oncology. 88: 27-35. PMID 18217207 DOI: 10.1007/S11060-008-9526-4 |
0.43 |
|
| 2006 |
Pöpperl G, Götz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC, Tatsch K. Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. European Journal of Nuclear Medicine and Molecular Imaging. 33: 792-800. PMID 16550381 DOI: 10.1007/s00259-005-0053-7 |
0.338 |
|
| 2005 |
Pöpperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspötter M, Tonn JC, Tatsch K. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging. 32: 1018-25. PMID 15877226 DOI: 10.1007/s00259-005-1819-7 |
0.328 |
|
| Show low-probability matches. |